# Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

> **NCT04906395** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tolmar Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TOL2506
- **DRUG:** Tamoxifen
- **DRUG:** Letrozole Tablets
- **DRUG:** Anastrozole Tablets
- **DRUG:** Exemestane Tablets

## Key facts

- **NCT ID:** NCT04906395
- **Lead sponsor:** Tolmar Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906395, "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04906395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*